| Immunogenicity of allogeneic mesenchymal stem cells S Schu, M Nosov, L O'Flynn, G Shaw, O Treacy, F Barry, M Murphy, ... Journal of cellular and molecular medicine 16 (9), 2094-2103, 2012 | 336 | 2012 |
| Anti‐donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? MD Griffin, AE Ryan, S Alagesan, P Lohan, O Treacy, T Ritter Immunology and cell biology 91 (1), 40-51, 2013 | 296 | 2013 |
| Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? P Lohan, O Treacy, MD Griffin, T Ritter, AE Ryan Frontiers in Immunology 8, 313870, 2017 | 125 | 2017 |
| Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation AE Ryan, P Lohan, L O'flynn, O Treacy, X Chen, C Coleman, G Shaw, ... Molecular Therapy 22 (3), 655-667, 2014 | 122 | 2014 |
| Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer G O'Malley, O Treacy, K Lynch, SD Naicker, NA Leonard, P Lohan, ... Cancer immunology research 6 (11), 1426-1441, 2018 | 71 | 2018 |
| A 3D view of colorectal cancer models in predicting therapeutic responses and resistance E Reidy, NA Leonard, O Treacy, AE Ryan Cancers 13 (2), 227, 2021 | 62 | 2021 |
| Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation O Treacy, L O’Flynn, AE Ryan, M Morcos, P Lohan, S Schu, M Wilk, ... American Journal of Transplantation 14 (9), 2023-2036, 2014 | 61 | 2014 |
| Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation P Lohan, N Murphy, O Treacy, K Lynch, M Morcos, B Chen, AE Ryan, ... Frontiers in immunology 9, 421158, 2018 | 48 | 2018 |
| Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation O Treacy, AE Ryan, T Heinzl, L O'Flynn, M Cregg, M Wilk, F Odoardi, ... Public Library of Science 7 (8), e42662, 2012 | 47 | 2012 |
| TNF‐α/IL‐1β—licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell‐mediated induction of Foxp3+ regulatory T cells in the lung N Murphy, O Treacy, K Lynch, M Morcos, P Lohan, L Howard, G Fahy, ... The FASEB Journal 33 (8), 9404-9421, 2019 | 46 | 2019 |
| Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival M Nosov, M Wilk, M Morcos, M Cregg, L O’Flynn, O Treacy, T Ritter American Journal of Transplantation 12 (5), 1313-1322, 2012 | 42 | 2012 |
| TGF-β1-licensed murine MSCs show superior therapeutic efficacy in modulating corneal allograft immune rejection in vivo K Lynch, O Treacy, X Chen, N Murphy, P Lohan, MN Islam, E Donohoe, ... Molecular Therapy 28 (9), 2023-2043, 2020 | 38 | 2020 |
| Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response P Lohan, O Treacy, K Lynch, F Barry, M Murphy, MD Griffin, T Ritter, ... Osteoarthritis and Cartilage 24 (3), 521-533, 2016 | 36 | 2016 |
| Interspecies incompatibilities limit the immunomodulatory effect of human mesenchymal stromal cells in the rat P Lohan, O Treacy, M Morcos, E Donohoe, Y O'donoghue, AE Ryan, ... Stem cells 36 (8), 1210-1215, 2018 | 26 | 2018 |
| Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation N Murphy, K Lynch, P Lohan, O Treacy, T Ritter Current opinion in organ transplantation 21 (6), 559-567, 2016 | 25 | 2016 |
| Donor Bone Marrow–derived Dendritic Cells Prolong Corneal Allograft Survival and Promote an Intragraft Immunoregulatory Milieu L O'flynn, O Treacy, AE Ryan, M Morcos, M Cregg, J Gerlach, L Joshi, ... Molecular Therapy 21 (11), 2102-2112, 2013 | 21 | 2013 |
| Corneal immunosuppressive mechanisms, anterior chamber-associated immune deviation (ACAID) and their role in allograft rejection O Treacy, G Fahy, T Ritter, L O’Flynn Suppression and Regulation of Immune Responses: Methods and Protocols …, 2016 | 18 | 2016 |
| Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular … SD Naicker, CL Feerick, K Lynch, D Swan, C McEllistrim, R Henderson, ... Oncoimmunology 10 (1), 1859263, 2021 | 14 | 2021 |
| Regulating immunogenicity and tolerogenicity of bone marrow-derived dendritic cells through modulation of cell surface glycosylation by dexamethasone treatment K Lynch, O Treacy, JQ Gerlach, H Annuk, P Lohan, J Cabral, L Joshi, ... Frontiers in Immunology 8, 1427, 2017 | 14 | 2017 |
| Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment H Egan, O Treacy, K Lynch, NA Leonard, G O’Malley, E Reidy, A O’Neill, ... Cell Reports 42 (5), 2023 | 12 | 2023 |
Thomas RitterProfessor of Medicine, University of Galway, IrelandVerified email at universityofgalway.ie
